Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
Income Statement
Follow revenue through to earnings.
Revenue
$44.64M
FY 2025 · Annual
-6.1% YoYOperating Income
-$6.35M
FY 2025 · Annual
Net Income
-$9.74M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1.54M | 21.25M | 47.54M | 44.64M |
| Cost of Revenue | 0 | 86K | 1.26M | 3.18M | 3.76M |
| Gross Profit | 0 | 1.45M | 19.99M | 44.35M | 40.88M |
| Gross Margin | — | 94.4% | 94.1% | 93.3% | 91.6% |
| Research & Development | 4.98M | 3.53M | 56K | 307K | 250K |
| Selling, General & Admin | 12.24M | 20.51M | 32.71M | 41.48M | 46.91M |
| Operating Expenses | 17.22M | 24.19M | 33.05M | 41.88M | 47.22M |
| Depreciation & Amortization | 16K | 149K | 287K | 800K | 103K |
| EBITDA | (17.22M) | (22.59M) | (12.36M) | 4.8M | (7.45M) |
| EBITDA Margin | — | -1471.5% | -58.2% | 10.1% | -16.7% |
| Operating Income | (17.22M) | (22.74M) | (13.06M) | 2.48M | (6.35M) |
| Operating Margin | — | -1481.3% | -61.4% | 5.2% | -14.2% |
| Interest Income | 54K | 195K | 441K | 1.59M | 787K |
| Interest Expense | 126K | 978K | 3.39M | 4.07M | 2.08M |
| Other Income / Expenses | (123K) | (976K) | (2.99M) | (2.55M) | (3.29M) |
| Income Before Tax | (17.35M) | (23.71M) | (16.05M) | (71K) | (9.64M) |
| Pre-Tax Margin | — | -1544.9% | -75.5% | -0.1% | -21.6% |
| Income Tax Expense | 0 | 0 | 0 | 365K | 106K |
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Net Margin | — | -1544.9% | -75.5% | -0.9% | -21.8% |
| EPS (Basic) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| EPS (Diluted) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| 26.01M | 26.28M | 26.57M | 27.29M | 28.58M | |
| 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
FENC Earnings Waterfall · TTM
NASDAQ:FENC · Revenue to Net Income
Key Ratios
Analysis
$51.0M of revenue converted into -$8.4M of net income for the selected period. Gross margin is 92.0% and net margin is -17.8%, showing how much revenue survives after costs and taxes. EPS is $-0.31, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
Market cap
$548.02M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Market cap
$448.71M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Market cap
$435.76M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Market cap
$320.09M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Market cap
$295.50M
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Market cap
$275.32M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Market cap
$193.69M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Market cap
$84.48M
Caribou Biosciences, Inc.
NASDAQ:CRBU
Market cap
$39.10M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Market cap
$29.11M
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 |
How much revenue does FENC generate?
Fennec Pharmaceuticals Inc. (FENC) reported $44.64M of revenue in fiscal 2025.
Is FENC profitable?
Fennec Pharmaceuticals Inc. (FENC) reported -$9.74M of net income, with a net margin of -21.8%.
Continue the stock analysis
Jump to another research area for this company.